Glucovance (glibenclamide + metformin): Uses, Dosage & Side Effects

What it's for (Indications)

Glibenclamide + metformin combination therapy is primarily indicated for the management of type 2 diabetes mellitus in adult patients.
This fixed-dose combination is typically prescribed when monotherapy with either metformin or a sulfonylurea (like glibenclamide) alone has failed to achieve adequate glycemic control.
It is also considered as an appropriate therapeutic option for patients who are already well-controlled on separate tablets of glibenclamide and metformin and would benefit from the convenience of a single tablet regimen.
The rationale for this combination lies in the complementary mechanisms of action of its two components, addressing different pathophysiological defects contributing to hyperglycemia in type 2 diabetes.
Glibenclamide stimulates insulin secretion from pancreatic beta cells, while metformin primarily reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
This synergistic approach allows for more comprehensive glycemic management.
It is crucial to note that this medication is not indicated for type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as these conditions require insulin therapy.

Dosage Information

Type	Guideline
Standard	The dosage of glibenclamide + metformin must be individualized based on the patient's current glycemic control, response to previous therapies, and tolerance, always aiming for the lowest effective dose. For patients not adequately controlled on metformin or glibenclamide monotherapy, the starting dose should be conservative, typically one tablet containing a lower strength of both components, taken once or twice daily with meals to minimize gastrointestinal side effects. Dosage adjustments should be made gradually, often in increments of one tablet strength every 1-2 weeks, based on blood glucose monitoring and HbA1c levels. The maximum daily dose for glibenclamide is generally 20 mg, and for metformin, it is 2000 mg. It is imperative that the physician carefully considers the individual maximum tolerated dose for each component. Dosage adjustments are also necessary in patients with renal impairment, and the drug is contraindicated in severe renal dysfunction due to the risk of lactic acidosis. Administration with meals is critical to optimize absorption and reduce gastrointestinal discomfort. Patients should be counselled on proper administration and adherence to the prescribed regimen to ensure efficacy and minimize adverse events.

Type

Guideline

Standard

The dosage of glibenclamide + metformin must be individualized based on the patient's current glycemic control, response to previous therapies, and tolerance, always aiming for the lowest effective dose. For patients not adequately controlled on metformin or glibenclamide monotherapy, the starting dose should be conservative, typically one tablet containing a lower strength of both components, taken once or twice daily with meals to minimize gastrointestinal side effects. Dosage adjustments should be made gradually, often in increments of one tablet strength every 1-2 weeks, based on blood glucose monitoring and HbA1c levels. The maximum daily dose for glibenclamide is generally 20 mg, and for metformin, it is 2000 mg. It is imperative that the physician carefully considers the individual maximum tolerated dose for each component. Dosage adjustments are also necessary in patients with renal impairment, and the drug is contraindicated in severe renal dysfunction due to the risk of lactic acidosis. Administration with meals is critical to optimize absorption and reduce gastrointestinal discomfort. Patients should be counselled on proper administration and adherence to the prescribed regimen to ensure efficacy and minimize adverse events.

Safety & Warnings

Common Side Effects

Patients receiving glibenclamide + metformin may experience a range of side effects, with some being more common than others.
The most frequently reported adverse reactions are often gastrointestinal in nature, primarily associated with metformin, and include diarrhea, nausea, vomiting, abdominal discomfort, and a metallic taste in the mouth.
These symptoms are typically transient and can often be mitigated by starting with a low dose and titrating slowly, and by taking the medication with meals.
Hypoglycemia is a significant concern, mainly due to the glibenclamide component, especially in elderly patients, those with renal or hepatic impairment, or individuals with poor nutritional intake.
Symptoms of hypoglycemia include dizziness, sweating, tremor, hunger, and confusion.
Other less common but potentially serious side effects include lactic acidosis, a rare but severe metabolic complication primarily associated with metformin, particularly in patients with predisposing conditions such as renal impairment or acute heart failure.
Hypersensitivity reactions, such as skin rashes or pruritus, may also occur.
Long-term metformin use has been associated with a decrease in vitamin B12 levels, potentially leading to megaloblastic anemia.
Patients should be educated on recognizing and reporting any adverse effects promptly to their healthcare provider.

Serious Warnings

Black Box Warning: WARNING: LACTIC ACIDOSIS. Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Onset is often subtle with non-specific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. It is characterized by elevated blood lactate levels (>5 mmol/Liter) and anion gap acidosis.
Several critical warnings and precautions are associated with glibenclamide + metformin therapy.
A prominent warning for metformin is the risk of lactic acidosis, a rare but serious metabolic complication with a high mortality rate.
Risk factors for lactic acidosis include renal impairment, advanced age, congestive heart failure, acute myocardial infarction, severe infection, dehydration, liver impairment, acute alcohol intake, and concomitant use of certain medications.
Renal function should be assessed before initiating therapy and periodically thereafter.
The glibenclamide component carries a significant risk of hypoglycemia, which can be severe and prolonged.
This risk is amplified in elderly patients, those with renal or hepatic insufficiency, malnutrition, or concurrent use of other hypoglycemic agents or alcohol.
Close monitoring of blood glucose is essential.
The medication is contraindicated in patients with severe renal dysfunction, metabolic acidosis (including diabetic ketoacidosis), and known hypersensitivity to either glibenclamide or metformin.
Concomitant use with iodinated contrast agents for radiographic procedures requires temporary discontinuation of metformin to prevent the risk of acute renal failure and subsequent lactic acidosis.
Patients should be advised about the signs and symptoms of lactic acidosis and hypoglycemia, and instructed to seek immediate medical attention if these occur.
Furthermore, caution is advised in patients with pre-existing heart failure due to potential fluid retention associated with sulfonylureas and the risk of lactic acidosis with metformin in this population.

How it Works (Mechanism of Action)

Glibenclamide + metformin is a synergistic combination designed to address the multifaceted pathophysiology of type 2 diabetes mellitus through distinct yet complementary mechanisms of action. Glibenclamide, a sulfonylurea, exerts its primary effect by stimulating insulin secretion from the pancreatic beta cells. It binds to the sulfonylurea receptor 1 (SUR1) on the beta-cell membrane, leading to the closure of ATP-sensitive potassium (KATP) channels. This closure causes depolarization of the beta-cell membrane, which in turn opens voltage-gated calcium channels, resulting in an influx of calcium ions. The increased intracellular calcium triggers the exocytosis of insulin granules, thereby increasing circulating insulin levels and lowering blood glucose. Glibenclamide's action is dependent on the presence of functional beta cells. Metformin, a biguanide, primarily acts by reducing hepatic glucose production. It achieves this by inhibiting gluconeogenesis and glycogenolysis in the liver, largely through the activation of AMP-activated protein kinase (AMPK). Additionally, metformin improves insulin sensitivity in peripheral tissues, particularly muscle, enhancing glucose uptake and utilization. It also decreases the intestinal absorption of glucose. Unlike sulfonylureas, metformin does not directly stimulate insulin secretion and therefore does not typically cause hypoglycemia when used as monotherapy. The combination of these two agents provides comprehensive glycemic control by simultaneously enhancing insulin secretion and improving insulin sensitivity while reducing glucose production and absorption, thereby targeting key defects in type 2 diabetes.